In this issue:
Leukaemia selection
• ASCT as first-line for CLL
• Bendamustine ±rituximab in relapsed CLL
• Adherence and loss of cytogenic response to imatinib in CML
• Outcome predictors after unrelated donor transplants in refractory AML
• Cytarabine dose for AML
• BRAF mutations in HCL
• LRF CLL4: TP53 mutations predict CLL outcomes
Lymphoma selection
• Romidepsin in peripheral T-cell lymphoma
• ASCT for early relapsed/refractory Hodgkin’s lymphoma
• Random skin/bone marrow biopsies for diagnosing IVL
Please login below to download this issue (PDF)